Objective:Osteosarcoma is a common primary highly malignant bone tumor.Kinesin family member 18B(K1F18B)has been identified as a potential oncogene involved in the development and metastasis of several cancer types.Wh...Objective:Osteosarcoma is a common primary highly malignant bone tumor.Kinesin family member 18B(K1F18B)has been identified as a potential oncogene involved in the development and metastasis of several cancer types.While KIF18B overexpression in osteosarcoma tissue is clearly detected,its specific function in the disease process remains to be established.Methods:K IF18B expression was assessed in osteosarcoma tissues and cells.We additionally evaluated the effects of KIF18B on proliferation,migration,and invasion of osteosarcoma cells,both in vitro and in vivo.Results:Our results showed overexpression of KIF18B in osteosarcoma tissues and cells.Knockdown of K IF18B induced G1/S phase arrest and significantly inhibited proliferation,migration,and invasion of osteosarcoma cells,both in vitro and in vivo.K IF18B regulated P-catenin expression at the transcriptional level by controlling nuclear aggregation of ATF2 and at the post-transcriptional level by interacting with the adenomatous polyposis coli(APC)tumor suppressor gene in osteosarcoma cells.Conclusions:KIF18B plays a carcinogenic role in osteosarcoma by regulating expression ofβ-catenin transcriptionally via decreasing nuclear aggregation of ATF2 or post-transcriptionally through interactions with APC.Our collective findings support the potential utility of KIF18B as a novel prognostic biomarker for osteosarcoma.展开更多
Objective: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor(DT) and analyze the prognostic factors.Methods:From November 2008 to April 2016,71 patients of inoperable DT were treated...Objective: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor(DT) and analyze the prognostic factors.Methods:From November 2008 to April 2016,71 patients of inoperable DT were treated with vinorelbine and low-dose methotrexate in the Department of Bone and Soft Tissue Tumors,Peking University Cancer Hospital&Institute,and enrolled in this retrospective study.The chemotherapy duration is one year.The efficacy of chemotherapy and the prognosis were observed.Results:Of the 71 patients,55% were female.Age of onset varied from 1 to 47 years,and the median age was 14years.Only 11(15.5%)cases suffered primary tumor.The distribution of the site of tumors was:31(43.7%)in the trunk,36(50.7%)in the limbs,and 4(5.6%)in the peritoneal and pelvic cavity.The size of tumor(the maximum diameter)differed from 2 to 37 cm with a mean of 9.3 cm.The median follow-up duration was 28(range,6–87)months.Common side effects included:nausea and vomiting,liver injury,bone marrow suppression and oral ulcers.When the chemotherapy finished,1(1.4%)case achieved complete response,24(33.8%)achieved partial response,37(52.1%)achieved stable disease and 9(12.7%)had progressive disease.The overall response rate was 87.3%.The progression-free survival(PFS)of the participants were from 6 to 87 months,and the 2-,3-and 5-year PFS was 79.9%,68.4% and 36.3%,respectively.No significant difference was identified in PFS in subgroups of gender,age of onset,age of chemotherapy,tumor site and tumor size.Conclusions:For recurrent,inoperable and progressive DT,enough course of chemotherapy with vinorelbine combined with low-dose methotrexate was an optional choice for local control.展开更多
基金grants from the National Natural Science Foundation of China(Grant No.81802689)China International Medical Foundation(Grant No.Z-2014-06-15331)Conflict of interest。
文摘Objective:Osteosarcoma is a common primary highly malignant bone tumor.Kinesin family member 18B(K1F18B)has been identified as a potential oncogene involved in the development and metastasis of several cancer types.While KIF18B overexpression in osteosarcoma tissue is clearly detected,its specific function in the disease process remains to be established.Methods:K IF18B expression was assessed in osteosarcoma tissues and cells.We additionally evaluated the effects of KIF18B on proliferation,migration,and invasion of osteosarcoma cells,both in vitro and in vivo.Results:Our results showed overexpression of KIF18B in osteosarcoma tissues and cells.Knockdown of K IF18B induced G1/S phase arrest and significantly inhibited proliferation,migration,and invasion of osteosarcoma cells,both in vitro and in vivo.K IF18B regulated P-catenin expression at the transcriptional level by controlling nuclear aggregation of ATF2 and at the post-transcriptional level by interacting with the adenomatous polyposis coli(APC)tumor suppressor gene in osteosarcoma cells.Conclusions:KIF18B plays a carcinogenic role in osteosarcoma by regulating expression ofβ-catenin transcriptionally via decreasing nuclear aggregation of ATF2 or post-transcriptionally through interactions with APC.Our collective findings support the potential utility of KIF18B as a novel prognostic biomarker for osteosarcoma.
文摘Objective: To assess the efficacy of conservative chemotherapy for inoperable desmoid tumor(DT) and analyze the prognostic factors.Methods:From November 2008 to April 2016,71 patients of inoperable DT were treated with vinorelbine and low-dose methotrexate in the Department of Bone and Soft Tissue Tumors,Peking University Cancer Hospital&Institute,and enrolled in this retrospective study.The chemotherapy duration is one year.The efficacy of chemotherapy and the prognosis were observed.Results:Of the 71 patients,55% were female.Age of onset varied from 1 to 47 years,and the median age was 14years.Only 11(15.5%)cases suffered primary tumor.The distribution of the site of tumors was:31(43.7%)in the trunk,36(50.7%)in the limbs,and 4(5.6%)in the peritoneal and pelvic cavity.The size of tumor(the maximum diameter)differed from 2 to 37 cm with a mean of 9.3 cm.The median follow-up duration was 28(range,6–87)months.Common side effects included:nausea and vomiting,liver injury,bone marrow suppression and oral ulcers.When the chemotherapy finished,1(1.4%)case achieved complete response,24(33.8%)achieved partial response,37(52.1%)achieved stable disease and 9(12.7%)had progressive disease.The overall response rate was 87.3%.The progression-free survival(PFS)of the participants were from 6 to 87 months,and the 2-,3-and 5-year PFS was 79.9%,68.4% and 36.3%,respectively.No significant difference was identified in PFS in subgroups of gender,age of onset,age of chemotherapy,tumor site and tumor size.Conclusions:For recurrent,inoperable and progressive DT,enough course of chemotherapy with vinorelbine combined with low-dose methotrexate was an optional choice for local control.